Overview

IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective observational study of 30 adult CIDP patients who receive home IVIg infusion services from AxelaCare Health Solutions, LLC. The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Collaborators:
AxelaCare Health Solutions, LLC
BriovaRx Infusion Services
CSL Behring
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin